MEDIA ROOM



  • Visual inspection of by-pass syringes

    Sanofi Pasteur and MSD end joint vaccines business in Europe

    Paris, France – January 2, 2017 - Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations. The change in operations took effect January 1, 2017.

    - 01/02/2017



Media Contact Press only

Contacts

Phone: +33(0)4 37 37 50 38

E-mail: media@sanofipasteur.com

U.S. Media

Phone: +1-570-957-0717

E-mail: MediaUS@sanofipasteur.com